logo-loader
viewEnvisagenics

Envisagenics using SpliceCore platform and A.I. to find hidden cures faster

Envisagenics, Inc CEO Maria Luisa Pineda sat down with Proactive’s Christine Corrado at BIO CEO in New York. The New York-based biotechnology company is leveraging artificial intelligence and RNA-splicing analytics for discovery and development of disease-specific therapeutics. The privately-held company was recently awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). 

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

2 days, 3 hours ago

2 min read